Medical oncologist @WinshipAtEmory specializing in treatment of and research to improve the care of patients with breast and gynecologic cancers. #bcsm#gynsm
After being announced to be positive, the TROPION-Breast01 phase 3 trial officially joins the already stellar list of abstracts planned to be presented at #ESMO23! #bcsm@myESMO
🌍TROPiCS-02🌍
HR+ mBC endocrine-R ⚠️ highly pretreated ❗️unmet need 🚦
✅OS 14·4 mo vs 11·2 mo HR 0·79 (irresp Trop-2 exp)
✅ORR Saci vs CT ➡️OR 1·63
✅TTD and QoL 4·3 mo vs 3·0 mo ➡️HR 0·75 and fatigue 2·2 mo vs 1·4 mo➡️HR 0·73
@Oncoalert#OncoalertAF
https://t.co/G4C9IlPiN4
@esrajustesra@quirogad@amybeumer@TumorBoardTues We don't know a lot about this, because MAINTAIN was mostly ribo after palbo - but in the right patient with slow progression, it would not be unreasonable in my mind to do this and watch closely!